PDF下载 ( 226 KB)
Current situation and prospect of chemotherapy and biotherapy for advanced pancreatic cancer
-
摘要:
<正>胰腺癌是人类恶性程度最高的实体肿瘤之一,生长迅速,转移早。根据美国最新统计资料,胰腺癌死亡人数在恶性肿瘤总死亡人数中排名第四位[1]。80%以上患者在诊断时已是晚期,且不能行手术切
-
[1]Jemal A, Siegel R, Ward E, et al.Cancer statistics, 2009[J].CA Cancer J Clin, 2009, 59 (4) ∶225-249. [2]Li D, Xie K, Wolff R, et al.Pancreatic cancer[J].Lancet, 2004, 363 (9414) ∶1049-1057. [3]倪泉兴, 傅德良.基于肿瘤生物学特性进行胰腺癌综合治疗[J].外科理论与实践, 2006, 11 (6) ∶471-474. [4]Sultana A, Smith CT, Cunningham D, et al.Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer[J].J Clin Oncol, 2007, 25 (18) ∶2607-2615. [5]3rd BHA, Moore MJ, Andersen J, et al.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for pa-tients with advanced pancreas cancer:a randomized trial[J].J Clin Oncol, 1997, 15 (6) ∶2403-2413. [6]Tempero M, Plunkett W, Van Haperen V R, et al.Randomized phase II comparison of dose-intense gemcitabine:thirty-minute infusion and fixed dose rate infusion in patients with pancreatic ade-nocarcinoma[J].J Clin Oncol, 2003, 21 (18) ∶3402-3408. [7]Heinemann V, Boeck S, Hinke A, et al.Meta-analysis of random-ized trials:evaluation of benefit from gemcitabine-based combina-tion chemotherapy applied in advanced pancreatic cancer[J].BMC Cancer, 2008, 8 (1) ∶82. [8]Bria E, Milella M, Gelibter A, et al.Gemcitabine-based combina-tions for inoperable pancreatic cancer:have we made real progress-A meta-analysis of20phase3trials[J].Cancer, 2007, 110 (3) ∶525-533. [9]Banu E, Banu A, Fodor A, et al.Meta-analysis of randomised tri-als comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer[J].Drugs Aging, 2007, 24 (10) ∶865-879. [10]Xie DR, Liang HL, Wang Y, et al.Meta-analysis on inoperable pancreatic cancer:a comparison between gemcitabine-based combi-nation therapy and gemcitabine alone[J].World J Gastroenterol, 2006, 12 (43) ∶6973-6981. [11]Schneider BP, Ganjoo KN, Seitz DE, et al.Phase II study of gem-citabine plus docetaxel in advanced pancreatic cancer:a Hoosier On-cology Group study[J].Oncology, 2003, 65 (3) ∶218-223. [12]O'Reilly EM, Abou-Alfa GK.Cytotoxic therapy for advanced pan-creatic adenocarcinoma[J].Semin Oncol, 2007, 34 (4) ∶347-353. [13]Klaassen DJ, MacIntyre JM, Catton GE, et al.Treatment of locally unresectable cancer of the stomach and pancreas:a randomized com-parison of5-fluorouracil alone with radiation plus concurrent and maintenance5-fluorouracil--an Eastern Cooperative Oncology Group study[J].J Clin Oncol, 1985, 3 (3) ∶373-378. [14]Chauffert B, Mornex F, Bonnetain F, et al.Phase III trial compa-ring intensive induction chemoradiotherapy (60Gy, infusional5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer.Definitive results of the2000-01FFCD/SFRO study[J].Ann Oncol, 2008, 19 (9) ∶1592-1599. [15]Loehrer PJ, Powell ME, Cardenes HR, et al.A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer:E4201[J].J Clin Oncol, 2008, 26 (Suppl15) ∶4506. [16]Pelzer U KK, Stieler J SI, Heil G GM, et al.A randomized trial in patients with gemcitabine refractory pancreatic cancer.Final results of the CONKO003study[J].J Clin Oncol, 2008, 26 (Suppl15) ∶4508. [17]Lemoine NR.Molecular advances in pancreatic cancer[J].Diges-tion, 1997, 58 (6) ∶550-556. [18]Sakorafas GH, Tsiotos GG.Molecular biology of pancreatic cancer:potential clinical implications[J].BioDrugs, 2001, 15 (7) ∶439-452. [19]Mahalingam D, Giles F.Challenges in developing targeted therapy for pancreatic adenocarcinoma[J].Expert Opin Ther Targets, 2008, 12 (11) ∶1389-1401. [20]Gangarosa LM, Sizemore N, Graves-Deal R, et al.A raf-inde-pendent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells[J].J Biol Chem, 1997, 272 (30) ∶18926-18931. [21]Rivera F, Lopez-Tarruella S, Vega-Villegas ME, et al.Treat-ment of advanced pancreatic cancer:from gemcitabine single agent to combinations and targeted therapy[J].Cancer Treat Rev, 2009, 35 (4) ∶335-339. [22]Moore MJ, Goldstein D, Hamm J, et al.Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer:a phase III trial of the National Cancer Institute of Canada Clinical Trials Group[J].J Clin Oncol, 2007, 25 (15) ∶1960-1966. [23]Van Cutsem E, Vervenne WL, Bennouna J, et al.Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in pa-tients with metastatic pancreatic cancer[J].J Clin Oncol, 2009, 27 (13) ∶2231-2237. [24]Gjertsen MK, Bakka A, Breivik J, et al.Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation[J].Lancet, 1995, 346 (8987) ∶1399-1400. [25]Gjertsen MK, Buanes T, Rosseland AR, et al.Intradermal ras pep-tide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant:Clinical and immunological responses in patients with pancreatic adenocarcinoma[J].Int J Cancer, 2001, 92 (3) ∶441-450. [26]Gilliam AD Topuzov EG, Garin AM et al.Randomised, double blind, placebo-controlled, multi-centre, group-sequential trial of G17DT for patients with advanced pancreatic cancer unsuitable or unwilling to take chemotherapy[J].Proc Am Soc Clin Oncol, 2004, 22 (14S) ∶2511. [27]Laheru D, Yeo C, Biedrzycki B, et al.Safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas[J].J Clin On-col, 2007, 25 (18s) ∶3010. [28]Wobser M, Keikavoussi P, Kunzmann V, et al.Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2restricted peptide derived from the universal tumor antigen sur-vivin[J].Cancer Immunol Immunother, 2006, 55 (10) ∶1294-1298. [29]Gaudernack GBT, Meo M.Clinical trials of a peptide based vaccine targeting telomerase[J].Proc Am Soc Clin Oncol, 2003, 22 (166) ∶A666. [30]Yamamoto K, Ueno T, Kawaoka T, et al.MUC1peptide vaccina-tion in patients with advanced pancreas or biliary tract cancer[J].Anticancer Res, 2005, 25 (5) ∶3575-3579. [31]Gilliam AD, Watson SA.G17DT:an antigastrin immunogen for the treatment of gastrointestinal malignancy[J].Expert Opin Biol Ther, 2007, 7 (3) ∶397-404. [32]Petrulio CA, Kaufman HL.Development of the PANVAC-VF vac-cine for pancreatic cancer[J].Expert Rev Vaccines, 2006, 5 (1) ∶9-19. [33]Kyte JA.Cancer vaccination with telomerase peptide GV1001[J].Expert Opin Investig Drugs, 2009, 18 (5) ∶687-694. [34]Buanes J, Maurel J, Liauw W, et al.A randomized phase III study of gemcitabine (G) versus GV1001in sequential combination with G in patients with unresectable and metastatic pancreatic cancer (PC) [J].J Clini Oncol, 2009, 27 (15S) ∶4601. [35]Stift A, Friedl J, Dubsky P, et al.Dendritic cell-based vaccina-tion in solid cancer[J].J Clin Oncol, 2003, 21 (1) ∶135-142. [36]Vlad AM, Kettel JC, Alajez NM, et al.MUC1immunobiology:from discovery to clinical applications[J].Adv Immunol, 2004, 82∶249-293. [37]Kalady MF, Onaitis MW, Emani S, et al.Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancre-atic cancer T cells[J].J Gastrointest Surg, 2004, 8 (2) ∶175-81;discussion181-182. [38]Ouchi KF, Yanagisawa M, Sekiguchi F, et al.Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models[J].Cancer Chemother Pharmacol, 2006, 57 (5) ∶693-702. [39]Kulke MH, Blaszkowsky LS, Ryan DP, et al.Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer[J].J Clin Oncol, 2007, 25 (30) ∶4787-4792. -
本文二维码
计量
- 文章访问数: 2244
- HTML全文浏览量: 1
- PDF下载量: 1304
- 被引次数: 0
下载:
